Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS* StudyAnne Vincent‐Salomon(Institut Curie), V Le Doussal(Hôpital René Huguenin)HistopathologyMarch 24, 200310.1046/j.1365-2559.2003.01598.xCited by 121SaveCiteExport RISWatch citationsRelated PapersHER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process|Cancer|2002|114